Teva says oral MS drug laquinimod may reduce brain tissue damage

TEL AVIV (Reuters) – Israel’s Teva Pharmaceutical Industries and Sweden’s Active Biotech said a Phase III clinical trial of laquinimod, an oral treatment for multiple sclerosis, demonstrated a beneficial impact on brain tissue damage. The study found that, compared with a placebo, patients treated with laquinimod had decreased rates in brain tissue damage shown by various MRI markers, specifically decreased rates of white matter, grey matter and thalamic atrophy, the companies said on Tuesday. …